UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 2, 2021

 

Aditxt, Inc.

(Exact name of registrant as specified in its charter)

  

Delaware   001-39336   82-3204328
(State or other jurisdiction
of incorporation) 		  (Commission File Number)   (IRS Employer
Identification No.)

 

737 N. Fifth Street, Suite 200

Richmond, VA

  23219
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 870-1200

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   ADTX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

Attached as Exhibit 99.1 to this Current Report on Form 8-K is an updated version of Aditxt, Inc.’s (the “Company”) investor presentation, which may be used in presentations to investors from time to time in the future.

 

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Investor Presentation

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ADITXT, INC.
     
Date: August 2, 2021 By: /s/ Corinne Pankovcin
    Corinne Pankovcin
    Chief Financial Officer

 

 

2

 

Exhibit 99.1

  

Œ Œ

 

 

2

 

 

3

 

 

4

 

 

Delta variant: ‘A perfect storm is brewing’ in certain parts America, health official explains Dr. Vin Gupta encourages J&J vaccine recipients to get a Pfizer or Moderna booster Delta variant now makes up 83% of cases, CDC director says, pressed on booster shots 5

 

 

6

 

 

 

 

• • • • • 8

 

 

Œ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 9

 

 

ΠRBD lgG Predicate (PCR) Mean + 3 SD NEW (MULTIPLE X ) A (TP) B (FP) C (FN) D (TN) 70 2 1 77 RBD lgM Predicate (PCR) Mean + 3 SD NEW (MULTIPLE X ) A (TP) B (FP) C (FN) D (TN) 62 3 9 76 RBD lgA Predicate (PCR) Mean + 3 SD NEW (MULTIPLE X ) A (TP) B (FP) C (FN) D (TN) 65 2 6 77 Overall Predicate (PCR) Mean + 3 SD NEW (MULTIPLE X ) A (TP) B (FP) C (FN) D (TN) 70 0 1 79 n : 150 n : 150 n : 150 n : 150 Concordant Result : 147 Concordant Result : 138 Concordant Result : 142 Concordant Result : 149 Discordant Result : 3 Discordant Result : 12 Discordant Result : 8 Discordant Result : 1 Relative Sensitivity: 98.6% Relative Sensitivity: 87.3% Relative Sensitivity: 91.5% Relative Sensitivity: 98.6% Relative Specificity: 97.5% Relative Specificity: 96.2% Relative Specificity: 97.5% Relative Specificity: 100.0% Concordance (Correlation) 0.980 Concordance (Correlation) 0.920 Concordance (Correlation) 0.947 Concordance (Correlation) 0.993 Positive Predictive Value: 97.2% Positive Predictive Value: 95.4% Positive Predictive Value: 97.0% Positive Predictive Value: 100.0% Negative Predictive Value: 98.7% Negative Predictive Value: 89.4% Negative Predictive Value: 92.8% Negative Predictive Value: 98.8% False Positive Rate: 2.8% False Positive Rate: 4.6% False Positive Rate: 3.0% False Positive Rate: 0.0% False Negative Rate: 1.3% False Negative Rate: 10.6% False Negative Rate: 7.2% False Negative Rate: 1.3% 10

 

 

AditxtScore Œ Cellular Immunity Assessment • • • Chen G, Liu H, Tyan D. FlowSpot: Real time prediction and monitoring of cellular immune profiles for responses to pathogens, vaccines, therapeutics, and transplantation. Manuscript submitted for publication. 11

 

 

1 2 3 ΠΠ12

 

 

ΠNO EXPOSURE NATURAL EXPOSURE VACCINE - INDUCED 13

 

 

AditxtScore’s Leadership Team Œ Œ 14

 

 

  15

 

 

Operat i on Rei m bursement C o mmercial Regulation Channel P a rtners 16

 

 

• • • CLIA - certified AditxtScore Ρ operation 17

 

 

Π18

 

 

FUTURE APPLICATIONS B R A IN THYROID CARDIO - MET A BOLIC GUT HEALTH DI A BETES BONES AND JOINTS HORMONE IMB A L A N C ES 19

 

 

AditxtScore Œ for Type - 1 Diabetes: Early Detection of Auto - antibodies • • • 20

 

 

 

 

22

 

 

Πx x x 23

 

 

Œ ENCODES TARGET PRO T EIN ENCODES PRO - APOP T OTIC PROTEIN Plasmid DNA inducing tolerance - inducing target protein Plasmid DNA inducing natural ‘programmed’ cell death 24

 

 

Œ • Œ • • • Œ 25

 

 

AditxtReprogramming’s Leadership Team 26

 

 

Lungs 3 - year survival rate of 68% Liver 70% Last 5 years or more Tissues 1 in 20 Americans will benefit from tissue transplants Pancreas Improve lives for an average of 10+ Years Corneas Can help improve sight for 20 Years Intestines N E A R LY 3000 LIVES Improved in the US to date Kidneys Improve lives for an average 12 - 15 Years Heart 5 - year survival rate of 70% or more 27

 

 

Π21 Days 58 Days Π1 0 1 5 2 0 2 5 3 0 3 5 4 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 ADi Tx of NOD mice at >200 mg/dL Age (weeks) Fasting Blood Glucose (mg/dL) 1 2 3 4 5 6 7 8 9 10 11 12 Psoriasis Induced - Untreated Psoriasis Induced - ADi Treated Increase in Skin Thickness 0 0,1 0,2 0,3 Change in thickness (mm) Psoriasis Induced - Untreated Psoriasis Induced - ADi Treated Increase in Scaling 0 0,5 1 1,5 Scaling Score (range = 0 - 4) 28

 

 

29

 

 

. 30

 

 

31

 

 

Hub of discovery and product development CLIA - certified AditxtScore Ρ operation 32 Hub of capital markets, investor and media relations, and business development

 

 

33

 

 

• • • • • 34